ReviewExpert review of pharmacoeconomics & outcomes research2026
Obstetric pharmacoeconomics.
Review in Expert review of pharmacoeconomics & outcomes research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
introductionPharmacoeconomic principles are increasingly shaping modern obstetric pharmacology as maternal therapeutics become more complex, costly, and precision-driven. Rising rates of hypertensive disorders of pregnancy, gestational diabetes, obesity, maternal cardiovascular disease, and medically complicated pregnancies have intensified the need for cost-effective therapeutic strategies that optimize maternal and neonatal outcomes while minimizing unnecessary healthcare expenditure. AREAS COVERED: This review examines contemporary pharmacoeconomic concepts in obstetric pharmacology, including cost-effectiveness analysis, quality-adjusted life years, implementation science, and value-based maternal therapeutics. Major domains reviewed include antihypertensive therapy, aspirin prophylaxis, diabetes pharmacotherapy, antiretroviral therapy in pregnancy, anticoagulation, perinatal mental health, lactation, fetal therapeutics, pharmacogenomics, precision dosing, digital health integration, and emerging artificial intelligence applications in maternal fetal medicine. The review further explores linked maternal-child outcome modeling, implementation-sensitive economic evaluation, and the growing role of pharmacometrics and biomarker-guided therapeutics in precision pregnancy care. The review also proposes a life-course framework linking pregnancy therapeutics to inter-generational health, implementation outcomes, and sustainable maternal healthcare systems globally. EXPERT OPINION: Obstetric pharmacology is entering a precision-medicine era where therapeutic value will depend on biologic profiling, implementation feasibility, and long-term maternal-child outcomes. Future pharmacoeconomic frameworks should integrate precision therapeutics, biomarker-guided strategies, real-world effectiveness, and lifelong maternal cardiovascular risk reduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.